Key Highlights

● Organigram agreed to acquire all Aurora common shares under a British Columbia plan of arrangement.

● Stock owners can choose cash, Organigram shares or a blend.

● British American Tobacco will subscribe to new Organigram shares to help fund the cash.

● Completion is aimed at January, subject to court, regulatory and German clearance.

Aurora Cannabis (NASDAQ:ACB) has agreed to be acquired by Organigram in a cash-and-stock arrangement announced on Tuesday, ending weeks of uncertainty created by an unsolicited bid from Curaleaf. A joint press release, furnished to the U.S. securities regulator on a current report for foreign issuers, describes a plan of arrangement under British Columbia law in which every Aurora common share would be exchanged for value paid in cash, Organigram shares, or a mix of the two.

The agreement was approved unanimously by both boards after a special committee of independent Aurora directors reviewed a market check that reached several parties. The announcement says the price is well above Aurora's unaffected share price from the day before Curaleaf went public with its approach, and also above the value implied by Curaleaf's amended proposal. Aurora's board had rejected that proposal and urged stock owners to take no action.

British American Tobacco, already the largest outside owner of Organigram, is part of the plan through a private Placement of new Organigram shares that would close alongside the arrangement. A bank Credit Facility rounds out the funding.

What exactly did Organigram and Aurora agree to?

Under the arrangement agreement, Organigram would acquire all of the issued common shares of Aurora. The structure is a statutory plan of arrangement, a court-supervised route common in Canadian corporate transactions that lets a deal bind all stock owners once the required votes and a final court order are secured. Aurora would become part of the Organigram group if the transaction completes.

The headline price is expressed in Canadian dollars per Aurora share, and the companies say it values Aurora at roughly half a billion Canadian dollars on a fully diluted basis. Because part of the payment is in Organigram shares, the effective value moves with Organigram's trading price. The press release anchors its figure to a recent volume-weighted average price for Organigram, so the number quoted is a snapshot rather than a fixed guarantee.

Both companies list on Nasdaq and the Toronto Stock Exchange, which is why the announcement reached U.S. regulators as well as Canadian ones. The full arrangement agreement is to be filed on the Canadian disclosure system, and that document will contain terms the press release leaves out, including any break fee and the outside date for completion.

How can Aurora stock owners choose to be paid?

Each Aurora stock owner can elect one of three payment forms. The first is all cash at the headline price. The second is a fixed exchange ratio of Organigram shares for each Aurora share. The third is a blend, with a smaller cash amount plus a smaller number of Organigram shares for each Aurora share. The blend is roughly an even split of the headline value between cash and stock.

Cash and share elections are subject to proration. The agreement sets a ceiling on total cash and a ceiling on the total number of Organigram shares that can be issued. If elections for either form exceed the ceiling, they are scaled back so that the totals stay within the limits, and the shortfall is filled with the other form of payment. A stock owner asking for all cash may therefore receive some shares, and the reverse is also true.

The structure also includes a tax-deferred rollover for eligible Canadian-resident Aurora stock owners who receive Organigram shares. Tax outcomes differ by Jurisdiction and personal circumstances, and the companies point stock owners to the forthcoming circular and their own advisers instead of offering general guidance.

Why does the Curaleaf bid keep appearing in the story?

Curaleaf, a large multistate cannabis operator based in Connecticut, made public an unsolicited offer for Aurora in the middle of August. The proposal combined Curaleaf subordinate voting shares with a smaller cash component and carried a cap on the value delivered per Aurora share, according to coverage from the trade press at the time. Aurora's board formed a special committee, rejected the approach, and told stock owners that no action was required.

The hostile bid was later amended, and Aurora responded with a notice of change to its directors' circular. A dispute also reached the Alberta Securities Commission, which dismissed Curaleaf's application to halt Aurora's at-the-market share program. The regulator's decision was announced by Aurora in late October, and the company said it had not used the program while the bid was pending.

Against that backdrop, the Organigram agreement is framed as a superior alternative. The press release says the price is above the value implied by the amended Curaleaf bid, and that Aurora's board reached its view unanimously after outside financial advisers delivered fairness opinions. Whether Curaleaf responds is not addressed in the announcement.

What role does British American Tobacco play?

British American Tobacco, through a subsidiary, already owns a substantial block of Organigram, including common and preferred shares. As part of this deal it has signed a Subscription Agreement to subscribe for a large batch of new Organigram shares at the same reference price used for the exchange ratio. The money raised is intended to pay the cash portion of the Aurora payment and related expenses.

The agreement includes a safeguard on voting. If the new shares would push the tobacco group above its voting ceiling, it receives non-voting convertible Preferred Shares instead, with conversion capped so that its voting stake stays at or below that ceiling after conversion. The same group has also signed an irrevocable voting agreement supporting the arrangement and opposing competing offers.

Because the tobacco group is a related party under Canadian securities rules, Organigram must seek approval from stock owners excluding the votes attached to the group's shares. The nominees of the group on the Organigram board abstained on the placement, and a board committee backed the transaction.

Which approvals must be secured before closing?

Aurora stock owners must approve the arrangement at a special meeting by at least two-thirds of the votes cast. A second, separate test applies as well: a simple majority of the votes cast once the votes of certain interested parties are removed, as required by Canadian rules on minority protection in Business combinations.

Organigram stock owners will vote separately on the share issuance and the private placement, again by a simple majority of votes cast excluding the tobacco group. The Toronto Stock Exchange must approve the listing of the new shares, and the Supreme Court of British Columbia must grant a final order after a hearing that confirms the process was fair.

Regulatory clearance is also needed, including a foreign ownership screening by the German federal Economics ministry, reflecting the European medical operations of both businesses. Directors and senior officers of each company have signed voting support agreements, which fall away if the arrangement agreement ends.

When could the transaction close?

The companies expect both special meetings to take place in December, with a joint information circular mailed to stock owners beforehand. If every approval arrives on schedule, completion is aimed at January. That timetable is ambitious by the standards of cross-border cannabis transactions, where regulatory reviews have sometimes run longer than first announced.

Until the circular is published, stock owners have no formal ballot to cast. Those who tendered into the Curaleaf bid are told they can withdraw through their broker or through the information agent named in Aurora's filings. Aurora's board continues to advise that no action be taken on the hostile offer.

The statement that a second notice of change to Aurora's directors' circular will follow indicates that the company intends to keep its disclosure on the hostile bid current while the Organigram process runs. That document should also record the board's reasons for preferring the new agreement.

How is the cash portion being financed?

Two sources are named. The first is the tobacco group's placement of new Organigram shares. The second is a set of senior secured credit facilities from ATB Financial, which has committed to underwrite the full amount and is not relying on syndication. The facilities amend and restate Organigram's existing credit line and add a term Loan Tranche that can partly fund the Aurora payment at closing.

The facilities mature three years after closing and carry interest tied to ATB benchmark rates plus a Margin that depends on the ratio of net Funded Debt to Earnings before interest, tax, Depreciation and amortization. Covenants include a ceiling on that Leverage Ratio and a floor on fixed-charge coverage, which will shape how aggressively the combined business can spend after closing.

An earlier tranche of the same term facility was drawn to finance Organigram's Acquisition of Sanity Group, a German medical cannabis company, and remains outstanding. The new tranche is available only once conditions are met, including a final court order and the closing of committed Equity proceeds.

What would the combined company look like?

The companies describe a business with five production and distribution facilities certified to European good Manufacturing practice standards, drawing on Organigram's sites in Atlantic Canada, Quebec, Manitoba and Ontario and on Aurora's Canadian and German operations. Aurora's medical brands, including MedReleaf and Pedanios, would sit alongside Organigram's adult-use labels in Canada such as Edison and SHRED.

Aurora contributes a patient-access network and pharmacy relationships in Canada, along with medical Supply into Europe, Australia and New Zealand. Organigram brings recreational brands and, through Sanity Group, a German medical presence with its own product lines. The companies say routing international Demand to the lowest-cost facility is one of the main sources of the identified savings.

On ownership, Aurora stock owners would collectively own a little over a third of the combined company on a fully diluted economic basis and a larger share of the votes. The release does not name the combined company's ticker or specify the full post-closing board, so those details remain to be confirmed in the circular.

Where do the cost savings come from?

Management points to identified run-rate synergies of more than 50 million Canadian dollars. The sources listed are cross-promotion between the two Brand portfolios, greater procurement scale for inputs and packaging, consolidated distribution, lower public-company costs from running one listing instead of two, and better utilization of cultivation space across the network.

Synergy figures in cannabis mergers have a mixed record. Integration of cultivation sites, quality systems and licensed distribution channels takes time, and regulators in each province and country can slow changes. The companies do not provide a timetable for reaching the full run-rate, and the circular is expected to give a fuller bridge.

The savings claim also interacts with the financing. Higher debt service from the bank facilities and the issuance of a large number of new shares both dilute the benefit for existing stock owners, a point the independent fairness opinions, issued by BMO Capital Markets for Organigram and by Fort Capital Partners and Origin Merchant Partners for Aurora, are meant to address.

What does Aurora's own business bring to the table?

Aurora describes itself as a global medical cannabis leader. Its Canadian operations include a patient-access and pharmacy network, and its European arm supplies German and other markets from facilities certified to European standards. Earlier this year the company completed its acquisition of Safari Flower Co. and highlighted growing European cultivation and manufacturing capacity as strategically important.

The company is scheduled to report its second-quarter fiscal results on the twelfth of November, before the market opens, with a call hosted by Executive Chairman and Chief Executive Miguel Martin and the chief financial officer. Whether that report proceeds as planned in light of the pending transaction is not specified in the announcement, but the earlier notice of the call remains on the company's newsroom.

The report will be the first set of financial statements published after the agreement and could give stock owners fresh data on medical volumes, margins and cash before they vote.

How does the deal fit the wider cannabis sector?

The agreement lands in a period of consolidation across the industry, as licensed producers in Canada contend with price pressure in the adult-use market and look to medical exports for steadier demand. Readers following Cannabis Stocks will notice that several large operators now pair a Canadian base with German or other European licences, which are valued for higher-priced medical sales.

The involvement of a global tobacco company as the anchor stock owner in the acquirer is a reminder that large consumer groups still view regulated cannabis as a long-term category even after earlier write-downs. For smaller listed names, a successful combination could raise the benchmark for what a strategic partner is willing to underwrite.

For index followers, the combined entity could be larger and more liquid than either business alone. The companies themselves cite greater index eligibility and free float as an intended benefit, while Aurora's U.S.-listed shares are currently small-cap names that sit on the edge of broad benchmarks such as the Russell 2000.

What remains uncertain for Aurora Cannabis?

Several points are open. The break fee and outside date are not in the press release. The reaction of Curaleaf is unknown, as is whether any competing proposal emerges, since the voting agreement and deal protections are designed to discourage one. The share exchange ratio is fixed, so the value received by Aurora stock owners who elect shares will move with Organigram's trading price until closing.

Regulatory clearance in Germany is a specific condition, and court approval requires a showing that the arrangement is fair and reasonable to those affected. Both are standard steps, but neither is a formality. The vote by Organigram stock owners, with the tobacco group excluded, is an independent test that does not depend on the outcome at Aurora.

Readers wanting the final terms should wait for the circular and the filed arrangement agreement.